30 July 2019 ORYZON Reports Financial Results and Corporate Update for the First Half Ended June 30, 2019
29 July 2019 ORYZON Announces End of Patient Recruitment for its Phase IIa trials in aggression with vafidemstat: REIMAGINE and REIMAGINE-AD
16 July 2019 ORYZON presents data from ETHERAL Phase IIa trial at the 2019 Alzheimer's Association International Conference in Los Angeles
10 July 2019 ORYZON to present data from ETHERAL Phase IIa trial at the 2019 Alzheimer's Association International Conference in Los Angeles
14 June 2019 ORYZON presents preliminary dose finding results of Phase II trial with iadademstat in AML
3 June 2019 ORYZON to present first clinical data from ALICE Phase IIa trial with iadademstat at the 24th Congress of the European Hematology Association
29 May 2019 ORYZON announces First Patient in the US in ETHERAL-US: a Phase IIa clinical trial with vafidemstat in Alzheimer’s Disease